Supplemental Figures

Supplemental Figure 1. Simplified diagram of the matching process.

Supplemental Figure 2. Propensity score distributions for (A) the largest cohort from AChEI trials and (B) the largest cohort from memantine trials.

Supplemental Figure 3. Intent-to-treat hazard ratios for the association between AChEI initiation or memantine initiation and 11 quality-of-care outcomes among individuals with Alzheimer's Disease.

Supplemental Figure 4. Intent-to-treat hazard ratios for the association between memantine initiation and 11 quality-of-care outcomes, stratified by concurrent AChEI use.

Supplemental Figure 5. Per protocol hazard ratios for the association between AChEI or memantine initiation and 11 quality-of-care outcomes.

Supplemental Figure 6. Intent-to-treat hazard ratios for the association between AChEI initiation and 11 quality-of-care outcomes, stratified by concurrent memantine use.

Supplemental Figure 1. Simplified diagram of matching process. Person A represents an individual in the memantine initiator arm of the trial. Person B and Person C would be eligible matches for this participant, while Persons D-F would be ineligible.



Supplemental Figure 2. Propensity score distributions for (A) the largest cohort from AChEI trials and (B) the largest cohort from memantine trials. These distributions reflect all propensity scores (i.e. before the exclusion of extreme propensity scores).



Supplemental Figure 3. Intent-to-treat hazard ratios for the association between AChEI initiation or memantine initiation and 11 quality-of-care outcomes among individuals with Alzheimer's Disease. Models used IPTW-stabilized weights with trimming of extreme propensity scores, and were adjusted for race, ethnicity, sex, other anti-dementia medication use, UC site, count of encounters in the year prior to baseline, count of prescriptions in the year prior to baseline, Charlson Comorbidity Index (CCI), prior neurology visit, history of sensory impairment, history of mobility problems, age, most recent cognitive impairment diagnosis, trial year, and deciles of propensity score.



Supplemental Figure 4. Intent-to-treat hazard ratios for the association between memantine initiation and 11 quality-of-care outcomes, stratified by concurrent AChEI use. Models used IPTW-stabilized weights with trimming of extreme propensity scores, and were adjusted for race, ethnicity, sex, UC site, count of encounters in the year prior to baseline, count of prescriptions in the year prior to baseline, Charlson Comorbidity Index (CCI), prior neurology visit, history of sensory impairment, history of mobility problems, age, most recent cognitive impairment diagnosis, trial year, and deciles of propensity score.



Supplemental Figure 5. Per protocol hazard ratios for the association between AChEI or memantine initiation and 11 quality-of-care outcomes. In these per protocol models, initiators were censored at first 60-day lapse in their medication use and non-initiators were censored when they initiated the anti-dementia drug of interest. Models used IPTW-stabilized weights with trimming of extreme propensity scores, and were adjusted for race, ethnicity, sex, other anti-dementia medication use, UC site, count of encounters in the year prior to baseline, count of prescriptions in the year prior to baseline, Charlson Comorbidity Index (CCI), prior neurology visit, history of sensory impairment, history of mobility problems, age, most recent cognitive impairment diagnosis, trial year, and deciles of propensity score.



Supplemental Figure 6. Intent-to-treat hazard ratios for the association between AChEI initiation and 11 quality-of-care outcomes, stratified by concurrent memantine use. Models used IPTW-stabilized weights with trimming of extreme propensity scores, and were adjusted for race, ethnicity, sex, UC site, count of encounters in the year prior to baseline, count of prescriptions in the year prior to baseline, Charlson Comorbidity Index (CCI), prior neurology visit, history of sensory impairment, history of mobility problems, age, most recent cognitive impairment diagnosis, trial year, and deciles of propensity score.



Supplemental Tables

Supplemental Table 1. SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) codes used for measuring cognitive impairment, quality-of-care outcomes, and covariates.

Supplemental Table 2. Characteristics of cohorts used in AChEI and memantine trials before and after dropping extreme propensity scores.

Supplemental Table 3. Descriptive characteristics of largest analytic cohort for memantine initiators and matched non-initiators after IPTW weights were applied.

Supplemental Table 4. Descriptive characteristics of largest analytic cohort for AChEI initiators and matched non-initiators after IPTW weights were applied.

Supplemental Table 5. Incidence rates of quality-of-care outcomes by cohort.

Supplemental Table 6. Intent-to-treat hazard ratios for the association between memantine initiation and 11 quality-of-care outcomes, overall and stratified by cognitive impairment diagnosis.

Supplemental Table 7. Proportion of non-initiators with prescriptions for memantine or AChEIs by time after matched date.

Supplemental Table 8. Intent-to-treat hazard ratios for the association between AChEI initiation and 11 quality-of-care outcomes, overall and stratified by cognitive impairment diagnosis.

Supplemental Table 9. Calculated e-values and inverse of the e-value for primary intent-to-treat hazard ratios for the associations between AChEI initiation, memantine initiation, and 11 quality-of-care outcomes.

Supplemental Table 10. Predictors (odds ratios) of ever use of memantine and AChEIs in the All of Us cohort, including all sociodemographic, health behavior, and clinical covariates.

Supplemental Table 1. SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) codes used for measuring cognitive impairment, quality-of-care outcomes, and covariates.

Variable	SNOMED CT Code
Cognitive Impairment Diagnoses in Primary Care	
Alzheimer's Disease and Related Dementias	14070001, 288631000119104, 1591000119103, 1591000119103, 31081000119101, 416780008, 1591000119103, 10349009, 16276361000119109, 191449005, 288631000119104, 191455000, 26929004, 288631000119104, 26929004, 25772007, 416975007, 371024007, 288631000119104, 26929004, 191461002, 1591000119103, 191452002, 191451009, 1591000119103, 52448006, 70936005, 288631000119104, 288631000119104
Mild Cognitive Impairment	386805003, 110352000
Memory loss	88822006, 51921000, 48167000
Quality-of-care Outcomes	
Delirium	191492000, 191507002, 2776000, 62476001, 419284004
Depression	46206005, 430852001, 191616006, 715924009, 19527009, 191613003, 46244001, 15639000, 68019004, 36474008, 76105009, 94921000119107, 79298009, 76441001, 66344007, 191610000, 35489007, 36923009, 40379007, 596004, 70747007, 78667006, 18818009, 33135002, 191611001
Falls	218250005, 161898004
Fecal incontinence	249515001, 439158007, 72042002, 71820002
Hip fractures	263234002, 208578003, 28576007, 26442006, 263233008, 6628008, 1144498009, 208526001, 208551000, 208588002, 208558006, 210967007, 263232003, 198741000000106, 1705000, 66926007, 20100009, 445899009, 705090003, 52450003, 30905007, 275340006, 79978005, 208580009, 208579006, 275341005, 445875009, 41191003, 428112005, 703994007, 25415003, 17194005, 19652000, 198751000000109, 84320000, 208589005, 263225007, 361119006, 359820003, 30489009, 263231005, 275343008, 208587007, 275342003, 79484004, 62125005
Urinary incontinence	397878005, 129847007, 444620007, 4985009, 8009008, 129853007, 236632007, 398064005, 448521006, 413343005, 165232002, 87557004, 58972000, 236655005, 60241006, 786457000
Covariates	
Sensory impairments	15188001, 85571008, 427772009, 73415002, 788953003, 95820000, 1230412003, 3561000119106, 79471008, 721294001, 162344009, 232325008, 8531006, 343087000, 89496002, 397540003, 218951000119100, 432141000124105, 397543001, 397542006, 397541004, 815051000000106, 813891000000107, 813901000000108, 813871000000108, 813881000000105, 8771000119104, 39139002, 65956007
Mobility problems	719232003, 228147004, 8510008, 302043000, 82971005, 160685001, 225612007, 225601007, 302002000, 22631008, 228158008, 427512004, 44695005

Supplemental Table 2. Characteristics of cohorts used in AChEI and memantine trials before and after dropping extreme propensity scores.

Outcome	Number in cohort	Number in cohort after dropping extreme propensity scores	Number of initiators in final sample	Unique individuals in final sample	Mean difference* in birth year within matched pairs
AChEI Trials					
Antipsychotics	46,786	44,354	7,488	16,574	0.003
Benzodiazepines	30,504	28,907	4,883	9,796	0.005
Death	58,306	55,226	9,326	21,060	0.002
Delirium	56,003	53,115	8,972	20,423	0.002
Depression	36,466	34,462	5,816	12,838	0.006
Emergency visits	58,306	55,226	9,326	21,060	0.002
Falls	56,930	53,846	9,090	20,763	0.002
Fecal incontinence	56,037	53,052	8,959	20,354	0.002
Hip fractures	56,476	53,521	9,038	20,568	0.002
Hospitalizations	58,306	55,226	9,326	21,060	0.002
Urinary incontinence	45,639	43,375	7,329	16,738	0.003
Memantine Trials					
Antipsychotics	27,030	25,615	4,327	11,702	0.002
Benzodiazepines	18,756	17,744	2,995	7,288	0
Death	36,106	34,102	5,757	15,946	0.002
Delirium	34,326	32,437	5,476	15,247	0.002
Depression	20,806	19,632	3,316	8,708	0.003
Emergency visits	36,106	34,102	5,757	15,946	0.002
Falls	35,009	33,076	5,581	15,379	0.002
Fecal incontinence	34,320	32,428	5,474	15,160	0.002
Hip fractures	34,867	33,082	5,590	15,460	0.002
Hospitalizations	36,106	34,102	5,757	15,946	0.002
Urinary incontinence	27,624	26,075	4,401	12,140	0.002

* Difference is defined as birth year of the initiator minus birth year of the matched non-initiator.

Supplemental Table 3. Descriptive characteristics of largest analytic cohort for memantine initiators and matched non-initiators after IPTW weights were applied.

Characteristic		Initiators	Matched non-initiators	Total
Covariates				
Male (%)		35.27	35.76	35.67
Racial Identity (%)				
	Asian	13.12	14.14	13.96
	Black	7.25	7.21	7.22
	Other	8.97	8.75	8.79
	Unknown	7.45	8.13	8.01
	White	63.22	61.77	62.03
Hispanic Identity (%)				
	Yes	11.26	10.69	10.79
	No	82.53	83.01	82.93
	Unknown	6.22	6.3	6.28
UC-Site (%)				
	UC1	14.00	13.01	13.19
	UC2	25.19	25.66	25.57
	UC3	32.55	33.67	33.48
	UC4	0.26	0.13	0.15
	UC5	14.86	13.95	14.11
	UC6	13.15	13.58	13.5
AChEI Use at Trial (%)		44.7	43.76	43.93
Number of prescriptions in prior year (mean)		37.96	32.34	33.24
Number of healthcare encounters in prior year (mean)		42.66	34.23	35.71
Charlson Comorbidity Index (mean)		1.93	1.76	1.79
Prior neurology visit (%)		28.45	26.06	25.98
History of sensory impairment (%)		23.28	23.56	23.59
History of mobility problems (%)		14.23	11.63	11.57
Matched factors				
Age (years, mean)		78.76	78.88	78.86
Cognitive impairment diagnosis (%)				
	ADRD	62.33	68.54	67.44
	MCI	11.14	10.07	10.26
	Memory loss	26.54	21.39	22.29
Trial Year (%)				
	2011-2015	21.04	22.7	22.41
	2016-2020	36.88	39.34	38.91
	2021-2024	42.08	37.96	38.69

Supplemental Table 4. Descriptive characteristics of largest analytic cohort for AChEI initiators and matched non-initiators after IPTW weights were applied.

Characteristic		Initiators	Matched non-initiators	Total
Covariates				
Male (%)		37.51	35.84	36.17
Racial Identity (%)				
	Asian	13.03	13.42	13.34
	Black	8.89	7.08	7.43
	Other	9.28	8.71	8.82
	Unknown	6.55	8.03	7.73
	White	62.25	62.77	62.67
Hispanic Identity (%)				
	Yes	9.24	10.43	10.19
	No	85.41	84.06	84.33
	Unknown	5.35	5.51	5.48
UC-Site (%)				
	UC1	14.38	13.36	13.56
	UC2	28.59	27.77	27.93
	UC3	30.45	30.76	30.7
	UC4	0.12	0.12	0.12
	UC5	14.09	13.93	13.96
	UC6	12.38	14.06	13.73
Memantine Use at Trial (%)		10.25	9.5	9.65
Number of prescriptions in prior year (mean)		54.66	36.28	39.92
Number of healthcare encounters in prior year (mean)		67.67	40.93	46.22
Charlson Comorbidity Index (mean)		1.98	1.59	1.67
Prior neurology visit (%)		23.31	21.45	21.45
History of sensory impairment (%)		29.44	24.03	24.01
History of mobility problems (%)		18.32	10.73	10.68
Matched factors				
Age (years, mean)		79.11	78.54	78.65
Cognitive impairment diagnosis (%)				
	ADRD	50.98	47.8	48.43
	MCI	18.5	15.88	16.39
	Memory loss	30.52	36.32	35.18
Trial Year (%)				
	2011-2015	17.35	24.65	23.21
	2016-2020	37.7	38.82	38.6
	2021-2024	44.94	36.53	38.2

Supplemental Table 5. Incidence rates of quality-of-care outcomes by cohort.

Outcome	Average Length of Follow-up (sd)	Number of cases	Observed person-years	Incidence Rate per 1,000 person-years
AChEI Trials				
Antipsychotics	3.56 (2.96)	11,882	157,732.8	75.33
Benzodiazepines	3.42 (3.01)	9,413	98,755.36	95.32
Death	4.06 (3.12)	21,120	224,373.28	94.13
Delirium	3.94 (3.08)	3,236	209,419.98	15.45
Depression	3.65 (3.1)	5,782	125,620.22	46.03
Emergency visits	2.92 (2.76)	18,040	161,281.07	111.85
Falls	3.99 (3.1)	1,524	215,103.32	7.08
Fecal incontinence	3.95 (3.08)	2,198	209,633.25	10.48
Hip fractures	3.95 (3.1)	1,946	211,380.44	9.21
Hospitalizations	3.17 (2.81)	16,699	175,150.9	95.34
Urinary incontinence	3.6 (2.99)	7,309	155,938.09	46.87
Memantine Trials				
Antipsychotics	3.31 (2.87)	7,430	84,909.91	87.5
Benzodiazepines	3.29 (2.9)	4,932	58,419.24	84.42
Death	3.74 (2.99)	14,098	127,392.22	110.67
Delirium	3.68 (2.98)	2,027	119,518.05	16.96
Depression	3.42 (2.97)	3,363	67,061.48	50.15
Emergency visits	2.78 (2.67)	10,205	94,760.43	107.69
Falls	3.69 (2.98)	898	122,119.51	7.35
Fecal incontinence	3.65 (2.93)	1,194	118,327.57	10.09
Hip fractures	3.72 (2.99)	1,173	123,159.95	9.52
Hospitalizations	2.96 (2.72)	10,231	100,943.31	101.35
Urinary incontinence	3.39 (2.85)	4,084	88,501.02	46.15

Supplemental Table 6. Intent-to-treat hazard ratios for the association between memantine initiation and 11 quality-of-care outcomes, overall and stratified by cognitive impairment diagnosis.

Outcome	**Hazard Ratio (95% CI)**			
	All	**ADRD**	**MCI**	**Memory Loss**
Antipsychotics	1.6 (1.45-1.75)	1.6 (1.44-1.77)	1.3 (0.98-1.71)	1.55 (1.28-1.87)
Benzodiazepines	1.47 (1.3-1.67)	1.67 (1.44-1.94)	1.28 (0.88-1.85)	1.3 (1.03-1.64)
Death	1.03 (0.96-1.11)	0.94 (0.87-1.01)	1.21 (0.87-1.69)	1.39 (1.17-1.66)
Delirium	1.28 (1.11-1.48)	1.4 (1.19-1.64)	0.65 (0.4-1.03)	1.31 (0.92-1.87)
Depression	1.44 (1.26-1.64)	1.4 (1.22-1.62)	1.85 (1.31-2.61)	1.46 (1.04-2.04)
Emergency visits	1.19 (1.08-1.3)	1.23 (1.11-1.37)	1.17 (0.92-1.49)	1.1 (0.92-1.32)
Falls	1.21 (0.96-1.51)	1.19 (0.88-1.62)	1.07 (0.55-2.1)	1.2 (0.79-1.83)
Fecal incontinence	1.34 (1.1-1.62)	1.38 (1.1-1.73)	0.84 (0.43-1.65)	1.31 (0.87-1.99)
Hip fractures	1.25 (1.03-1.51)	1.12 (0.89-1.41)	2.39 (1.07-5.32)	1.17 (0.74-1.87)
Hospitalizations	1.15 (1.05-1.28)	1.1 (0.98-1.22)	1.19 (0.84-1.69)	1.16 (0.97-1.39)
Urinary incontinence	1.28 (1.15-1.43)	1.32 (1.16-1.51)	0.82 (0.57-1.2)	1.29 (1.03-1.61)

Supplemental Table 7. Proportion of non-initiators with prescriptions for memantine or AChEIs by time after matched date.

Anti-dementia medication	Sample size of non-initiators	Proportion with prescription for anti-dementia medication by endpoint; n (%)			
		Year 1	Year 2	Year 5	Ever
AChEIs	45,900	3,375 (7.35)	4,792 (10.44)	6,673 (14.54)	7,157 (15.59)
Memantine	28,345	1,340 (4.73)	2,042 (7.2)	2,875 (10.14)	3,143 (11.09)

Supplemental Table 8. Intent-to-treat hazard ratios for the association between AChEI initiation and 11 quality-of-care outcomes, overall and stratified by cognitive impairment diagnosis.

Outcome	**Hazard Ratio (95% CI)**			
	All	**ADRD**	**MCI**	**Memory Loss**
Antipsychotics	1.67 (1.51-1.84)	1.47 (1.3-1.66)	1.39 (1.13-1.72)	1.72 (1.45-2.04)
Benzodiazepines	1.2 (1.04-1.39)	1.32 (1.13-1.52)	0.94 (0.67-1.31)	1.01 (0.85-1.19)
Death	0.99 (0.92-1.05)	0.87 (0.79-0.95)	1.15 (0.92-1.44)	1.37 (1.24-1.51)
Delirium	1.37 (1.17-1.61)	1.3 (1.05-1.61)	1.66 (1.15-2.41)	1.36 (1.09-1.68)
Depression	1.86 (1.67-2.06)	2.08 (1.8-2.41)	1.73 (1.39-2.15)	1.44 (1.24-1.66)
Emergency visits	1.23 (1.14-1.34)	1.3 (1.16-1.45)	1.5 (1.24-1.82)	1.02 (0.89-1.17)
Falls	1.52 (1.16-1.99)	3.13 (2.19-4.49)	1.2 (0.8-1.8)	0.94 (0.7-1.26)
Fecal incontinence	1.23 (1.04-1.45)	1.36 (1.09-1.71)	1.34 (0.86-2.07)	0.9 (0.71-1.14)
Hip fractures	1.07 (0.91-1.25)	1.11 (0.89-1.38)	0.94 (0.64-1.37)	0.86 (0.63-1.17)
Hospitalizations	1.13 (1.03-1.24)	1.17 (1.04-1.32)	1.22 (0.98-1.51)	1 (0.87-1.16)
Urinary incontinence	1.24 (1.09-1.41)	1.17 (1.02-1.35)	1.09 (0.86-1.39)	1.15 (1-1.32)

Supplemental Table 9. Calculated e-values and inverse of the e-value for primary intent-to-treat hazard ratios for the associations between AChEI initiation, memantine initiation, and 11 quality-of-care outcomes. E-values were not calculated for estimates that were statistically insignificant and are blank in the table.

Outcome	**E-value, 1/E-value by anti-dementia medication**	
	AChEIs	**Memantine**
Antipsychotics	2.20, 0.46	2.11, 0.47
Benzodiazepines	1.53, 0.65	1.94, 0.52
Death	--	--
Delirium*	2.09, 0.48	1.88, 0.53
Depression	2.44, 0.41	1.89, 0.53
Emergency visits	1.58, 0.63	1.50, 0.67
Falls*	2.41, 0.41	--
Fecal incontinence*	1.76, 0.57	2.00, 0.50
Hip fractures*	--	1.80, 0.55
Hospitalizations	1.40, 0.71	1.45, 0.69
Urinary incontinence	1.59, 0.63	1.66, 0.60

*Considered a rare outcome, so the hazard ratio was considered an approximation of the risk ratio when calculating these e-values.

Supplemental Table 10. Predictors (odds ratios) of ever use of memantine and AChEIs in the All of Us cohort, including all sociodemographic, health behavior, and clinical covariates. Model 2 includes adjustment for all predictors and age, sex, and racial identity. Model 3 adds adjustment for ever use of the other anti-dementia medication.

Predictor	**Ever memantine use; OR (95% CI)**		**Ever AChEI use; OR (95% CI)**	
	Model 2	**Model 3**	**Model 2**	**Model 3**
Education (ref: Less than HS)				
High School	0.72 (0.47-1.1)	0.72 (0.45-1.15)	0.88 (0.64-1.2)	0.97 (0.69-1.35)
Some college	0.7 (0.46-1.05)	0.75 (0.48-1.18)	0.77 (0.56-1.04)	0.84 (0.6-1.17)
College or above	0.67 (0.44-1.01)	0.67 (0.42-1.07)	0.87 (0.64-1.18)	0.98 (0.7-1.37)
Missing	0.91 (0.42-1.99)	0.98 (0.41-2.38)	0.8 (0.44-1.46)	0.78 (0.41-1.5)
Smoking Status (ref: Non-smoker)				
Smoker	1.06 (0.84-1.34)	1.12 (0.88-1.45)	0.96 (0.82-1.14)	0.94 (0.79-1.12)
Missing	1.08 (0.54-2.18)	1.19 (0.55-2.58)	0.9 (0.54-1.48)	0.86 (0.5-1.48)
Alcohol use (ref: no)				
Yes	0.9 (0.63-1.27)	1.01 (0.69-1.47)	0.78 (0.61-0.99)	0.76 (0.58-0.99)
Missing	0.51 (0.19-1.35)	0.47 (0.16-1.38)	0.87 (0.48-1.58)	0.99 (0.53-1.86)
Income (ref: 35-75k)				
Less than 10k	1.03 (0.65-1.64)	1.02 (0.62-1.68)	0.93 (0.66-1.3)	0.93 (0.64-1.33)
10-25k	0.92 (0.61-1.37)	0.81 (0.53-1.25)	1.13 (0.85-1.48)	1.19 (0.88-1.59)
25-35k	0.87 (0.53-1.42)	0.78 (0.46-1.33)	0.99 (0.7-1.38)	1.02 (0.71-1.46)
More than 75k	0.73 (0.51-1.05)	0.79 (0.53-1.17)	0.75 (0.58-0.97)	0.8 (0.61-1.05)
Missing	1.09 (0.79-1.52)	1.05 (0.74-1.5)	1.03 (0.81-1.31)	1.01 (0.78-1.32)
Marital Status (ref: Married)				
Living with partner	0.15 (0.04-0.62)	0.15 (0.03-0.62)	0.69 (0.41-1.16)	0.91 (0.53-1.56)
Divorced	0.54 (0.38-0.76)	0.64 (0.45-0.92)	0.64 (0.51-0.81)	0.73 (0.57-0.93)
Separated	0.73 (0.39-1.37)	0.79 (0.39-1.58)	0.71 (0.44-1.14)	0.76 (0.46-1.27)
Widowed	0.65 (0.46-0.91)	0.77 (0.53-1.12)	0.7 (0.55-0.9)	0.75 (0.58-0.98)
Never married	0.51 (0.33-0.77)	0.62 (0.4-0.96)	0.5 (0.37-0.68)	0.55 (0.4-0.75)
Missing	0.39 (0.16-0.99)	0.49 (0.17-1.38)	0.49 (0.26-0.92)	0.62 (0.33-1.17)
General health (ref: Excellent)				
Very good	1.3 (0.77-2.21)	1.29 (0.73-2.27)	1.16 (0.81-1.66)	1.1 (0.75-1.62)
Good	1.1 (0.66-1.85)	1.12 (0.64-1.95)	1.04 (0.73-1.48)	1.03 (0.71-1.51)
Fair	1.21 (0.71-2.06)	1.25 (0.7-2.2)	1.04 (0.72-1.5)	1 (0.68-1.48)
Poor	1.07 (0.57-2)	1.04 (0.53-2.04)	1.04 (0.67-1.6)	1.06 (0.67-1.68)
Missing	1.99 (0.86-4.62)	1.65 (0.65-4.18)	1.92 (1.06-3.48)	1.72 (0.9-3.28)
Health care utilization	1 (1-1.01)	1 (1-1.01)	1 (1-1.01)	1 (1-1.01)
Health insurance (ref: no)				
Yes	1.18 (0.46-3)	1.14 (0.43-3.06)	1.12 (0.59-2.12)	1.07 (0.55-2.1)
Missing	1.67 (0.54-5.23)	1.53 (0.44-5.35)	1.29 (0.57-2.94)	1.12 (0.47-2.71)
Birth Country (ref: US)				
Outside US	1.12 (0.76-1.65)	1 (0.65-1.52)	1.23 (0.93-1.63)	1.21 (0.89-1.65)
Missing	1.38 (0.59-3.22)	1.17 (0.43-3.21)	1.62 (0.88-3)	1.57 (0.81-3.06)
Baseline cancer	0.99 (0.78-1.26)	0.91 (0.71-1.18)	1.18 (1-1.4)	1.21 (1.01-1.45)

Baseline hypertension	1.13 (0.84-1.53)	1.19 (0.86-1.63)	1.06 (0.86-1.31)	1.04 (0.83-1.3)
Baseline asthma	1.07 (0.82-1.4)	1.04 (0.78-1.39)	1.02 (0.84-1.23)	1.01 (0.83-1.24)
Baseline coronary heart disease	1.07 (0.81-1.42)	1.15 (0.84-1.56)	0.98 (0.8-1.2)	0.96 (0.77-1.19)
Baseline chronic kidney disease	1.07 (0.81-1.42)	1.13 (0.84-1.54)	0.91 (0.74-1.12)	0.88 (0.7-1.09)
Baseline dementia	1.18 (0.93-1.48)	1.11 (0.86-1.43)	1.06 (0.9-1.26)	1.02 (0.86-1.22)
Baseline heart failure	0.68 (0.38-1.24)	0.83 (0.44-1.58)	0.69 (0.46-1.05)	0.75 (0.48-1.15)
Baseline stroke	1.93 (1.08-3.45)	1.29 (0.68-2.45)	2.53 (1.64-3.92)	2.32 (1.45-3.72)
Baseline congestive heart failure	0.96 (0.5-1.83)	0.76 (0.38-1.53)	1.3 (0.83-2.04)	1.35 (0.84-2.15)
Baseline heart attack	0.97 (0.68-1.38)	1 (0.67-1.47)	0.95 (0.74-1.22)	0.95 (0.73-1.24)
Baseline diabetes	0.87 (0.68-1.13)	0.88 (0.67-1.16)	0.93 (0.78-1.12)	0.96 (0.79-1.17)
Baseline obesity	0.84 (0.66-1.07)	0.85 (0.66-1.09)	0.98 (0.82-1.16)	1.01 (0.85-1.22)
Ever use of other anti-dementia medication	--	12.99 (10.05-16.8)	--	12.81 (9.97-16.46)